Literature DB >> 28766235

Polymorphisms in Epithelial-Mesenchymal Transition-Related Genes and the Prognosis of Surgically Treated Non-small Cell Lung Cancer.

Yangki Seok1,2, Hyo-Gyoung Kang3,4, Shin Yup Lee1,5, Ji Yun Jeong6, Jin Eun Choi3,4, Deuk Kju Jung3,7, Cheng Cheng Jin3,7, Mi Jeong Hong3,7, Sook Kyung Do3,7, Won Kee Lee8, Ji Young Park6, Kyung Min Shin9, Seung Soo Yoo1,5, Jaehee Lee5, Sukki Cho10, Seung Ick Cha5, Chang Ho Kim5, Sanghoon Jheon10, Eung Bae Lee11,12, Jae Yong Park13,14,15,16,17.   

Abstract

BACKGROUND: This study was conducted to determine whether single-nucleotide polymorphisms (SNPs) in EMT-related genes may influence the prognosis of NSCLC after surgery.
METHODS: There were 88 SNPs in EMT-related genes evaluated in a discovery set of 376 patients who underwent curative surgery for NSCLC. Significantly, 14 SNPs were evaluated in a validation set of 428 patients. Luciferase assay and RT-PCR were conducted to examine functional relevance of polymorphisms.
RESULTS: Fourteen SNPs that were associated with survival outcomes in a discovery set were selected for validation. Among those, two SNPs (FOXF2 rs1711972A>C and HEYL rs784621G>A) were replicated in a validation study. In combined analysis, FOXF2 rs1711972 AC+CC genotype was associated with significantly better overall survival (OS) and disease-free survival (DFS) compared with AA genotype (adjusted hazard ratio [aHR] for OS = 0.67, 95% confidence interval [CI] 0.51-0.88, P = 0.004; and aHR for DFS = 0.77, 95% CI 0.62-0.95, P = 0.01). HEYL rs784621 AA genotype exhibited a significantly worse OS compared with GG+GA genotype (aHR for OS = 2.65, 95% CI 1.63-4.31, P = 8 × 10-5). FOXF2 rs1711972C allele had a significantly increased promoter activity than rs1711972A allele (P = 0.01), and HEYL rs784621A allele had a significantly lower promoter activity than rs784621G allele (P = 0.004). FOXF2 rs1711972A>C was significantly associated with increased FOXF2 mRNA expression.
CONCLUSIONS: FOXF2 rs1711972A>C and HEYL rs784621G>A were associated with survival outcomes of surgically treated NSCLC. These SNPs may help to identify patients at high risk of poor disease outcomes.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28766235     DOI: 10.1245/s10434-017-6002-4

Source DB:  PubMed          Journal:  Ann Surg Oncol        ISSN: 1068-9265            Impact factor:   5.344


  4 in total

1.  Genetic variants in epithelial-mesenchymal transition genes as predictors of clinical outcomes in localized prostate cancer.

Authors:  Yang Deng; Kunlin Xie; Christopher J Logothetis; Timothy C Thompson; Jeri Kim; Maosheng Huang; David W Chang; Jian Gu; Xifeng Wu; Yuanqing Ye
Journal:  Carcinogenesis       Date:  2020-08-12       Impact factor: 4.944

Review 2.  FOXF2 acts as a crucial molecule in tumours and embryonic development.

Authors:  Weihan He; Yuanbo Kang; Wei Zhu; Bolun Zhou; Xingjun Jiang; Caiping Ren; Weihua Guo
Journal:  Cell Death Dis       Date:  2020-06-05       Impact factor: 8.469

3.  The regulatory roles and mechanisms of the transcription factor FOXF2 in human diseases.

Authors:  Qiong Wu; Wei Li; Chongge You
Journal:  PeerJ       Date:  2021-03-02       Impact factor: 2.984

4.  Exosomal lncRNA SCIRT/miR-665 Transferring Promotes Lung Cancer Cell Metastasis through the Inhibition of HEYL.

Authors:  Zhengyang Wang; Minmin Lin; Lulu He; Hongyan Qi; Jing Shen; Kejing Ying
Journal:  J Oncol       Date:  2021-07-24       Impact factor: 4.375

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.